Skip to main content
Top
Published in: Reproductive Biology and Endocrinology 1/2019

Open Access 01-12-2019 | Contraception | Research

Effects of three long-acting reversible contraceptive methods on HIV target cells in the human uterine cervix and peripheral blood

Authors: Liping Li, Jie Zhou, Weijia Wang, Lina Huang, Jiaoqin Tu, Lyndsey Baiamonte, Moselle Stark, Mistie Mills, Thomas J. Hope, Erma Z. Drobnis, Alison J. Quayle, Danny J. Schust

Published in: Reproductive Biology and Endocrinology | Issue 1/2019

Login to get access

Abstract

Background

Hormonal contraceptives, particularly depot medroxyprogesterone acetate (DMPA), have been reported to be associated with substantially enhanced HIV acquisition; however, the biological mechanisms of this risk remain poorly understood. We aimed to investigate the effects of different hormonal contraceptives on the expression of the HIV co-receptors, CXCR4 and CCR5, on female endocervical and peripheral blood T cells.

Methods

A total of 59 HIV-negative women were enrolled, including 15 initiating DMPA, 28 initiating a levonorgestrel-releasing intrauterine device (LNG-IUD) and 16 initiating an etonogestrel (ETG)-delivering vaginal ring. Peripheral blood and endocervical cytobrush specimens were collected at enrollment and 3–4 weeks after contraception initiation to analyze the expression of CXCR4 and CCR5, on CD4+ and CD8+ T cells using flow cytometry.

Results

Administration of DMPA increased the percentages of CD4+ and CD8+ T cells expressing CCR5 in the endocervix but not in the peripheral blood. Administration of the LNG-IUD or the ETG vaginal ring did not affect the percentages of T lymphocytes expressing CXCR4 or CCR5 in the female cervix or peripheral blood.

Conclusions

Increase in the percentage of endocervical T cells expressing CCR5 upon DMPA exposure provides a plausible biological explanation for the association between DMPA use and an elevated risk of HIV infection.
Appendix
Available only for authorised users
Literature
1.
go back to reference UNAIDS. Global AIDS Update. Geneva: Joint United Nations Programme on HIV/AIDS; 2016. UNAIDS. Global AIDS Update. Geneva: Joint United Nations Programme on HIV/AIDS; 2016.
2.
go back to reference Abdool Karim Q, Sibeko S, Baxter C. Preventing HIV infection in women: a global health imperative. Clin Infect Dis. 2010;50:S122–9.CrossRef Abdool Karim Q, Sibeko S, Baxter C. Preventing HIV infection in women: a global health imperative. Clin Infect Dis. 2010;50:S122–9.CrossRef
3.
go back to reference Mavranezouli I. Health economics of contraception. Best Pract Res Clin Obstet Gynaecol. 2009;23:187–98.CrossRef Mavranezouli I. Health economics of contraception. Best Pract Res Clin Obstet Gynaecol. 2009;23:187–98.CrossRef
4.
go back to reference Wilcher R, Petruney T, Reynolds HW, Cates W. From effectiveness to impact: contraception as an HIV prevention intervention. Sex Transm Infect. 2008;84:ii54–60.CrossRef Wilcher R, Petruney T, Reynolds HW, Cates W. From effectiveness to impact: contraception as an HIV prevention intervention. Sex Transm Infect. 2008;84:ii54–60.CrossRef
5.
go back to reference Reynolds HW, Janowitz B, Homan R, Johnson L. The value of contraception to prevent perinatal HIV transmission. Sex Transm Dis. 2006;33:350–6.CrossRef Reynolds HW, Janowitz B, Homan R, Johnson L. The value of contraception to prevent perinatal HIV transmission. Sex Transm Dis. 2006;33:350–6.CrossRef
6.
go back to reference Sweat MD, O'Reilly KR, Schmid GP, Denison J, de Zoysa I. Cost-effectiveness of nevirapine to prevent mother-to-child HIV transmission in eight African countries. AIDS. 2004;18:1661–71.CrossRef Sweat MD, O'Reilly KR, Schmid GP, Denison J, de Zoysa I. Cost-effectiveness of nevirapine to prevent mother-to-child HIV transmission in eight African countries. AIDS. 2004;18:1661–71.CrossRef
7.
go back to reference Baeten JM, Lavreys L, Overbaugh J. The influence of hormonal contraceptive use on HIV-1 transmission and disease progression. Clin Infect Dis. 2007;45:360–9.CrossRef Baeten JM, Lavreys L, Overbaugh J. The influence of hormonal contraceptive use on HIV-1 transmission and disease progression. Clin Infect Dis. 2007;45:360–9.CrossRef
8.
go back to reference Govender Y, Avenant C, Verhoog NJ, Ray RM, Grantham NJ, Africander D, et al. The injectable-only contraceptive medroxyprogesterone acetate, unlike norethisterone acetate and progesterone, regulates inflammatory genes in endocervical cells via the glucocorticoid receptor. PLoS One. 2014;9:e96497.CrossRef Govender Y, Avenant C, Verhoog NJ, Ray RM, Grantham NJ, Africander D, et al. The injectable-only contraceptive medroxyprogesterone acetate, unlike norethisterone acetate and progesterone, regulates inflammatory genes in endocervical cells via the glucocorticoid receptor. PLoS One. 2014;9:e96497.CrossRef
9.
go back to reference Chandra N, Thurman AR, Anderson S, Cunningham TD, Yousefieh N, Mauck C, et al. Depot medroxyprogesterone acetate increases immune cell numbers and activation markers in human vaginal mucosal tissues. AIDS Res Hum Retrovir. 2013;29:592–601.CrossRef Chandra N, Thurman AR, Anderson S, Cunningham TD, Yousefieh N, Mauck C, et al. Depot medroxyprogesterone acetate increases immune cell numbers and activation markers in human vaginal mucosal tissues. AIDS Res Hum Retrovir. 2013;29:592–601.CrossRef
10.
go back to reference Achilles SL, Creinin MD, Stoner KA, Chen BA, Meyn L, Hillier SL. Changes in genital tract immune cell populations after initiation of intrauterine contraception. Am J Obstet Gynecol. 2014;211:489.e1–9.CrossRef Achilles SL, Creinin MD, Stoner KA, Chen BA, Meyn L, Hillier SL. Changes in genital tract immune cell populations after initiation of intrauterine contraception. Am J Obstet Gynecol. 2014;211:489.e1–9.CrossRef
11.
go back to reference Sciaranghella G, Wang C, Hu H, Anastos K, Merhi Z, Nowicki M, et al. CCR5 expression levels in HIV-uninfected women receiving hormonal contraception. J Infect Dis. 2015;212:1397–401.CrossRef Sciaranghella G, Wang C, Hu H, Anastos K, Merhi Z, Nowicki M, et al. CCR5 expression levels in HIV-uninfected women receiving hormonal contraception. J Infect Dis. 2015;212:1397–401.CrossRef
12.
go back to reference Byrne EH, Anahtar MN, Cohen KE, Moodley A, Padavattan N, Ismail N, et al. Association between injectable progestin-only contraceptives and HIV acquisition and HIV target cell frequency in the female genital tract in south African women: a prospective cohort study. Lancet Infect Dis. 2016;16:441–8.CrossRef Byrne EH, Anahtar MN, Cohen KE, Moodley A, Padavattan N, Ismail N, et al. Association between injectable progestin-only contraceptives and HIV acquisition and HIV target cell frequency in the female genital tract in south African women: a prospective cohort study. Lancet Infect Dis. 2016;16:441–8.CrossRef
13.
go back to reference Ralph LJ, McCoy SI, Shiu K, Padian NS. Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies. Lancet Infect Dis. 2015;15:181–9.CrossRef Ralph LJ, McCoy SI, Shiu K, Padian NS. Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies. Lancet Infect Dis. 2015;15:181–9.CrossRef
14.
go back to reference Morrison CS, Chen PL, Kwok C, Richardson BA, Chipato T, Mugerwa R, et al. Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. AIDS. 2010;24:1778–81.CrossRef Morrison CS, Chen PL, Kwok C, Richardson BA, Chipato T, Mugerwa R, et al. Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. AIDS. 2010;24:1778–81.CrossRef
15.
go back to reference Morrison CS, Chen PL, Kwok C, Baeten JM, Brown J, Crook AM, et al. Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis. PLoS Med. 2015;12:e1001778.CrossRef Morrison CS, Chen PL, Kwok C, Baeten JM, Brown J, Crook AM, et al. Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis. PLoS Med. 2015;12:e1001778.CrossRef
16.
go back to reference Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, et al. Hormonal contraceptive use and risk of HIV-1 transmission: a prospective cohort analysis. Lancet Infect Dis. 2012;12:19–26.CrossRef Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, et al. Hormonal contraceptive use and risk of HIV-1 transmission: a prospective cohort analysis. Lancet Infect Dis. 2012;12:19–26.CrossRef
17.
go back to reference Martin HL Jr, Nyange PM, Richardson BA, Lavreys L, Mandaliya K, Jackson DJ, et al. Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis. 1998;178:1053–9.CrossRef Martin HL Jr, Nyange PM, Richardson BA, Lavreys L, Mandaliya K, Jackson DJ, et al. Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis. 1998;178:1053–9.CrossRef
18.
go back to reference Crook AM, Ford D, Gafos M, Hayes R, Kamali A, Kapiga S, et al. Injectable and oral contraceptives and risk of HIV acquisition in women: an analysis of data from the MDP301 trial. Hum Reprod. 2014;29:1810–7.CrossRef Crook AM, Ford D, Gafos M, Hayes R, Kamali A, Kapiga S, et al. Injectable and oral contraceptives and risk of HIV acquisition in women: an analysis of data from the MDP301 trial. Hum Reprod. 2014;29:1810–7.CrossRef
19.
go back to reference Stringer EM, Kaseba C, Levy J, Sinkala M, Goldenberg RL, Chi BH, et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol. 2007;197:144.e1–8.CrossRef Stringer EM, Kaseba C, Levy J, Sinkala M, Goldenberg RL, Chi BH, et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol. 2007;197:144.e1–8.CrossRef
20.
go back to reference Stringer EM, Giganti M, Carter RJ, El-Sadr W, Abrams EJ, Stringer JS, et al. Hormonal contraception and HIV disease progression: a multicountry cohort analysis of the MTCT-plus initiative. AIDS. 2009;23:S69–77.CrossRef Stringer EM, Giganti M, Carter RJ, El-Sadr W, Abrams EJ, Stringer JS, et al. Hormonal contraception and HIV disease progression: a multicountry cohort analysis of the MTCT-plus initiative. AIDS. 2009;23:S69–77.CrossRef
21.
go back to reference Heffron R, Mugo N, Ngure K, Celum C, Donnell D, Were E, et al. Hormonal contraceptive use and risk of HIV-1 disease progression. AIDS. 2013;27:261–7.CrossRef Heffron R, Mugo N, Ngure K, Celum C, Donnell D, Were E, et al. Hormonal contraceptive use and risk of HIV-1 disease progression. AIDS. 2013;27:261–7.CrossRef
22.
go back to reference Morrison CS, Skoler-Karpoff S, Kwok C, Chen PL, van de Wijgert J, Gehret-Plagianos M, et al. Hormonal contraception and the risk of HIV acquisition among women in South Africa. AIDS. 2012;26:497–504.CrossRef Morrison CS, Skoler-Karpoff S, Kwok C, Chen PL, van de Wijgert J, Gehret-Plagianos M, et al. Hormonal contraception and the risk of HIV acquisition among women in South Africa. AIDS. 2012;26:497–504.CrossRef
23.
go back to reference Wall KM, Kilembe W, Vwalika B, Htee Khu N, Brill I, Chomba E, et al. Hormonal contraception does not increase women's HIV acquisition risk in Zambian discordant couples, 1994-2012. Contraception. 2015;91:480–7.CrossRef Wall KM, Kilembe W, Vwalika B, Htee Khu N, Brill I, Chomba E, et al. Hormonal contraception does not increase women's HIV acquisition risk in Zambian discordant couples, 1994-2012. Contraception. 2015;91:480–7.CrossRef
24.
go back to reference Clemetson DB, Moss GB, Willerford DM, Hensel M, Emonyi W, Holmes KK, et al. Detection of HIV DNA in cervical and vaginal secretions. Prevalence and correlates among women in Nairobi, Kenya. JAMA. 1993;269:2860–4.CrossRef Clemetson DB, Moss GB, Willerford DM, Hensel M, Emonyi W, Holmes KK, et al. Detection of HIV DNA in cervical and vaginal secretions. Prevalence and correlates among women in Nairobi, Kenya. JAMA. 1993;269:2860–4.CrossRef
25.
go back to reference Mugo NR, Heffron R, Donnell D, Wald A, Were EO, Rees H, et al. Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1 serodiscordant couples. AIDS. 2011;25:1887–95.CrossRef Mugo NR, Heffron R, Donnell D, Wald A, Were EO, Rees H, et al. Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1 serodiscordant couples. AIDS. 2011;25:1887–95.CrossRef
26.
go back to reference Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 1996;272:1955–8.CrossRef Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 1996;272:1955–8.CrossRef
27.
go back to reference Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996;381:661–6.CrossRef Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996;381:661–6.CrossRef
28.
go back to reference Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996;272:872–7.CrossRef Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996;272:872–7.CrossRef
29.
go back to reference Ficarra M, Ibana JS, Poretta C, Ma L, Myers L, Taylor SN, et al. A distinct cellular profile is seen in the human endocervix during chlamydia trachomatis infection. Am J Reprod Immunol. 2008;60:415–25.CrossRef Ficarra M, Ibana JS, Poretta C, Ma L, Myers L, Taylor SN, et al. A distinct cellular profile is seen in the human endocervix during chlamydia trachomatis infection. Am J Reprod Immunol. 2008;60:415–25.CrossRef
30.
go back to reference Pudney J, Quayle AJ, Anderson DJ. Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod. 2005;73:1253–63.CrossRef Pudney J, Quayle AJ, Anderson DJ. Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod. 2005;73:1253–63.CrossRef
31.
go back to reference Prakash M, Kapembwa MS, Gotch F, Patterson S. Higher levels of activation markers and chemokine receptors on T lymphocytes in the cervix than peripheral blood of normal healthy women. J Reprod Immunol. 2001;52:101–11.CrossRef Prakash M, Kapembwa MS, Gotch F, Patterson S. Higher levels of activation markers and chemokine receptors on T lymphocytes in the cervix than peripheral blood of normal healthy women. J Reprod Immunol. 2001;52:101–11.CrossRef
32.
go back to reference Yeaman GR, Howell AL, Weldon S, Demian DJ, Collins JE, O'Connell DM, et al. Human immunodeficiency virus receptor and coreceptor expression on human uterine epithelial cells: regulation of expression during the menstrual cycle and implications for human immunodeficiency virus infection. Immunology. 2003;109:137–46.CrossRef Yeaman GR, Howell AL, Weldon S, Demian DJ, Collins JE, O'Connell DM, et al. Human immunodeficiency virus receptor and coreceptor expression on human uterine epithelial cells: regulation of expression during the menstrual cycle and implications for human immunodeficiency virus infection. Immunology. 2003;109:137–46.CrossRef
33.
go back to reference Rosini S, Caltagirone S, Tallini G, Lattanzio G, Demopoulos R, Piantelli M, et al. Depletion of stromal and intraepithelial antigen-presenting cells in cervical neoplasia in human immunodeficiency virus infection. Hum Pathol. 1996;27:834–8.CrossRef Rosini S, Caltagirone S, Tallini G, Lattanzio G, Demopoulos R, Piantelli M, et al. Depletion of stromal and intraepithelial antigen-presenting cells in cervical neoplasia in human immunodeficiency virus infection. Hum Pathol. 1996;27:834–8.CrossRef
34.
go back to reference Hladik F, Sakchalathorn P, Ballweber L, Lentz G, Fialkow M, Eschenbach D, et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity. 2007;26:257–70.CrossRef Hladik F, Sakchalathorn P, Ballweber L, Lentz G, Fialkow M, Eschenbach D, et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity. 2007;26:257–70.CrossRef
35.
go back to reference Moore JP, Trkola A, Dragic T. Co-receptors for HIV-1 entry. Curr Opin Immunol. 1997;9:551–62.CrossRef Moore JP, Trkola A, Dragic T. Co-receptors for HIV-1 entry. Curr Opin Immunol. 1997;9:551–62.CrossRef
36.
go back to reference Smith-McCune KK, Hilton JF, Shanmugasundaram U, Critchfield JW, Greenblatt RM, Seidman D, et al. Effects of depot-medroxyprogesterone acetate on the immune microenvironment of the human cervix and endometrium: implications for HIV susceptibility. Mucosal Immunol. 2017;10(5):1270–8.CrossRef Smith-McCune KK, Hilton JF, Shanmugasundaram U, Critchfield JW, Greenblatt RM, Seidman D, et al. Effects of depot-medroxyprogesterone acetate on the immune microenvironment of the human cervix and endometrium: implications for HIV susceptibility. Mucosal Immunol. 2017;10(5):1270–8.CrossRef
37.
go back to reference Sheffield JS, Wendel GD Jr, McIntire DD, Norgard MV. The effect of progesterone levels and pregnancy on HIV-1 coreceptor expression. Reprod Sci. 2009;16:20–31.CrossRef Sheffield JS, Wendel GD Jr, McIntire DD, Norgard MV. The effect of progesterone levels and pregnancy on HIV-1 coreceptor expression. Reprod Sci. 2009;16:20–31.CrossRef
38.
go back to reference Killick S. Complete and robust ovulation inhibition with NuvaRing. Eur J Contracept Reprod Health Care. 2002;7(13–8):37–9.PubMed Killick S. Complete and robust ovulation inhibition with NuvaRing. Eur J Contracept Reprod Health Care. 2002;7(13–8):37–9.PubMed
39.
go back to reference Smith SM, Baskin GB, Marx PA. Estrogen protects against vaginal transmission of simian immunodeficiency virus. J Infect Dis. 2000;182:708–15.CrossRef Smith SM, Baskin GB, Marx PA. Estrogen protects against vaginal transmission of simian immunodeficiency virus. J Infect Dis. 2000;182:708–15.CrossRef
40.
go back to reference Hel Z, Stringer E, Mestecky J. Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection. Endocr Rev. 2010;31:79–97.CrossRef Hel Z, Stringer E, Mestecky J. Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection. Endocr Rev. 2010;31:79–97.CrossRef
Metadata
Title
Effects of three long-acting reversible contraceptive methods on HIV target cells in the human uterine cervix and peripheral blood
Authors
Liping Li
Jie Zhou
Weijia Wang
Lina Huang
Jiaoqin Tu
Lyndsey Baiamonte
Moselle Stark
Mistie Mills
Thomas J. Hope
Erma Z. Drobnis
Alison J. Quayle
Danny J. Schust
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Reproductive Biology and Endocrinology / Issue 1/2019
Electronic ISSN: 1477-7827
DOI
https://doi.org/10.1186/s12958-019-0469-8

Other articles of this Issue 1/2019

Reproductive Biology and Endocrinology 1/2019 Go to the issue